glp-1 drugs key developments 2025 RA prescription trends: January 2018 – September Understanding GLP-1s and their dynamic

In addition, fewer semaglutide-treated patients experienced deterioration in NYHA functional class (2.09% versus 5.24%, respectively

Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway

Weight loss is broadly viewed as positive, with leaner and smaller body sizes generally being more aligned with westernized body norms

It will be interesting to see how much these medications seem to help with arthritis pain based on weight loss alone versus via other mechanisms

In a subanalysis of SURPASS-3, tirzepatide 10 and 15 mg resulted also in a relative reduction in liver fat content by 4047% compared to 11% with insulin glargine at 52 weeks [44]